Peptide Comparison
Retatrutide vs Liraglutide
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Liraglutide has stronger documented evidence (FDA-Approved) than Retatrutide (Phase 3) while both occupy the glp-1 class. When clinical-evidence tier is the deciding factor, Liraglutide is the safer pick. Retatrutide may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| Retatrutide | Liraglutide | |
|---|---|---|
| Class | GIP/GLP-1/glucagon triple agonist | GLP-1 receptor agonist |
| Drug class | Metabolic & Weight | Metabolic & Weight |
| Mechanism | Simultaneous activation of GIP, GLP-1, and glucagon receptors for incretin + energy expenditure effects | GLP-1R agonist; albumin-binding fatty acid extends half-life |
| Route | SC injection | SC injection |
| Half-life | ~6 days | ~13 hrs |
| Dosage (research) | 2 mg SC weekly (TRIUMPH Phase 3 starting dose, escalate by 2 mg every fourth week per protocol, trial doses 1, 2, 4, 8, and 12 mg/wk) | 0.6 mg SC daily (Victoza/Saxenda label starting dose, escalate weekly by 0.6 mg to 1.8 mg/day for T2D per Victoza or 3 mg/day for obesity per Saxenda label) |
| Evidence tier | Phase 3 | FDA-Approved |
| Research depth | 217 indexed | 321 indexed |
| Availability | Investigational | Prescription |
| Reported risks | GI side effects; Phase 3 ongoing; long-term safety unknown | Nausea; vomiting; pancreatitis; gallbladder disease; thyroid C-cell tumor warning |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Retatrutide or Liraglutide?
Liraglutide has stronger documented evidence (FDA-Approved) than Retatrutide (Phase 3) while both occupy the glp-1 class. When clinical-evidence tier is the deciding factor, Liraglutide is the safer pick. Retatrutide may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between Retatrutide and Liraglutide?
Retatrutide is classed as GIP/GLP-1/glucagon triple agonist; Liraglutide is classed as GLP-1 receptor agonist. Reported mechanism: Retatrutide, Simultaneous activation of GIP, GLP-1, and glucagon receptors for incretin + energy expenditure effects; Liraglutide, GLP-1R agonist; albumin-binding fatty acid extends half-life. Reported half-life: Retatrutide, ~6 days; Liraglutide, ~13 hrs. Routes in published studies: Retatrutide, SC injection; Liraglutide, SC injection.
Which has stronger evidence, Retatrutide or Liraglutide?
Liraglutide has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Retatrutide is graded Phase 3, with 29 cited sources on its reference page and 217 indexed studies. Liraglutide is graded FDA-Approved, with 64 cited sources on its reference page and 321 indexed studies.
Which is more accessible, Retatrutide or Liraglutide?
Liraglutide is FDA-approved and Retatrutide is not. Catalog status: Retatrutide, Investigational; Liraglutide, Prescription.
Are Retatrutide and Liraglutide ever combined?
Retatrutide and Liraglutide appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…